+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Glioma Diagnosis and Treatment Market Size was valued at USD 3.6 Billion in 2022. The Glioma Diagnosis and Treatment market industry is projected to grow from USD 3.6 Billion in 2023 to USD 5.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.30% during the forecast period (2023 - 2032). Rising prevalence, increasing R&D, and favorable regulatory conditions for glioblastoma multiforme, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
The market is anticipated to grow as a result of a number of factors, including increased R&D, favorable regulatory settings, and the rising occurrence of glioblastoma multiforme. A strong pipeline is likely to significantly influence the glioblastoma multiforme (GBM) therapeutic market during the projected timeframe. The incidence of brain tumors is predicted to fuel market expansion over the course of the projection period. According to the Global Cancer Observatory, brain and CNS cancer claimed 251,329 lives and saw 308,102 new cases worldwide in 2020. Brain cancer is among the most fatal forms of the disease. Glioblastomas multiforme make up the bulk of malignant tumors, including up to 54% of gliomas and 16% of all primary brain tumors. Glioblastoma multiforme is more common in adults than in children, and as people age, their risk of developing it increases.
The market is predicted to be boosted in the coming years by the growing acceptance of novel medicines and combination therapies. For instance, in June 2019, the American Food and Drug Administration approved Pfizer's Zirabev, a biosimilar to Avastin, for the treatment of recurrent cancers like colorectal, non-small cell lung cancer, and glioblastoma. In the US, the company released its product in January 2020. Additionally, the possibility that goods could be made available in the coming years has increased as the U.S. FDA approved Samsung's BLA application for its SB8 bevacizumab copycat candidate in November 2019.
A personalized treatment strategy for glioblastoma multiforme is anticipated to become more important due to the heterogeneity of the tumor and variations in treatment approaches between patients. According to predictions, patients with glioblastoma multiforme will live longer if new treatments are accepted. The FDA's special designation of investigational medications is also thought to hasten the approval and commercialization of innovative therapies. For instance, the Denovo biopharma drug DB102 (enzastaurin) received fast track designation from the US FDA in July 2020 for the treatment of patients who had just received a glioblastoma diagnosis. Thus, driving the Glioma Diagnosis and Treatment market revenue.
The global Glioma Diagnosis and Treatment market segmentation, based on Type, includes primary tumors and secondary tumors. Primary segment dominated the global market in 2022. The fundamental cause of this development is the increased need for primary tumor therapy on a global scale.
The global Glioma Diagnosis and Treatment market segmentation, based on Diagnosis, includes neurological exam, computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, biopsy, molecular testing, electroencephalography (EEG), and others. The neurological exam segment dominated the global market in 2022. This is connected to the increased public awareness of the diagnosis of gliomas.
The global Glioma Diagnosis and Treatment market segmentation, based on Treatment, includes surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy. Radiation therapy segment dominated the global market in 2022. This is as a result of rising survival rates. Combining radiation therapy with chemotherapy and surgery is one treatment strategy.
The global Glioma Diagnosis and Treatment market segmentation, based on Grade, includes low grade glioma, high grade glioma, and recurrent high grade glioma. Low grade glioma segment dominated the global Glioma Diagnosis and Treatment market in 2022. This may be connected to adults being more likely to acquire low grade gliomas.
The global Glioma Diagnosis and Treatment market segmentation, based on Location, includes supratentorial and infratentorial. Supratentorial segment dominated the global Glioma Diagnosis and Treatment market in 2022. This is a result of the supratentorial region's rising glioma prevalence.
The global Glioma Diagnosis and Treatment market segmentation, based on End User, includes hospitals & clinics, diagnostic centers, medical research centers, and others. The hospitals & clinics segment dominated the global Glioma Diagnosis and Treatment market in 2022. This is because individuals increasingly prefer hospitals and dental offices because they frequently provide all treatments while utilizing cutting-edge technologies.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. The North America Glioma Diagnosis and Treatment Market dominated this market in 2022 (45.80%). Government support for the expansion of the healthcare sector, together with increased awareness of unusual ailments, simple access to top-notch medical facilities, and kind reimbursement policies, are some of the key factors driving regional market growth. Further, In the North American area, the U.S. Glioma Diagnosis and Treatment market had the biggest market share, while the Canada Glioma Diagnosis and Treatment market had the quickest rate of expansion.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Europe Glioma Diagnosis and Treatment market accounted for the healthy market share in 2022. A few of the key factors driving regional market expansion include the sizeable unmet demands in the industry, growing awareness of GBM, and a robust pipeline of compounds with the ability to pass the blood-brain barrier. Further, In the European region, the German Glioma Diagnosis and Treatment market had the biggest market share, and the U.K. Glioma Diagnosis and Treatment market had the quickest rate of growth.
The Asia Pacific Glioma Diagnosis and Treatment market is expected to register significant growth from 2023 to 2032. This is brought on by a number of factors, including the availability of generic temozolomide, a better economy, a rise in the number of elderly people, and increased healthcare spending. Moreover, In the Asia-Pacific region, the Indian Glioma Diagnosis and Treatment market had the quickest rate of growth while China's Glioma Diagnosis and Treatment market had the greatest market share.
Leading industry companies are making significant R&D investments in order to diversify their product offerings, which will drive the Glioma Diagnosis and Treatment market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants are also engaging in a number of strategic actions to increase their global footprint. The Glioma Diagnosis and Treatment sector needs to provide affordable products if it wants to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies employed by manufacturers in the worldwide Glioma Diagnosis and Treatment industry to assist customers and expand the market sector is local manufacturing to reduce operational costs. Some of the biggest benefits to medicine have recently come from the Glioma Diagnosis and Treatment sector. Major players in the Glioma Diagnosis and Treatment market, including Thermo Fisher Scientific Inc., Emcure Pharmaceuticals Ltd., Sigma-Aldrich Co., Pfizer Inc., Taj Pharmaceuticals Limited, Novartis International AG , Teva Pharmaceutical Industries Ltd., GE Healthcare, Siemens Healthineers, Philips Healthcare, Shimadzu Corporation, Toshiba Medical Systems Corporation, Merck & Co., Inc., F. Hoffmann-Le Roche AG, Arbor Pharmaceuticals, LLC, Sun Pharmaceutical Industries, Ltd., Amneal Pharmaceuticals. LLC, AstraZeneca, Carestream Health, and Hitachi Medical Corporation, are attempting to increase market demand by investing in research and development operations.
Northwest Biotherapeutics Inc. (NW Bio) is a biotechnology company in the development stage. It finds and develops products for cancer immunotherapy. Using its own cutting-edge technical platform, DCVax, the company develops prospective therapeutic product candidates. In a therapeutic vaccination known as DCVax, the patient's own dendritic cells serve as the therapeutic agent. In August 2022, the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) approved the Paediatric Investigation Plan (PIP) for the Company.
Diffusion Pharmaceuticals Inc. (Diffusion), formerly Diffusion Pharmaceuticals LLC, is a biotechnology company at the clinical stage. Therapies that meet standards of care are created. For solid tumors that are resistant to other forms of therapy, including numerous FDA-designated orphan indications, the company improves chemotherapy and radiation therapy. In July 2022, Diffusion Pharmaceuticals began a Phase II trial for patients with glioblastoma multiforme that evaluated tumour oxygenation using state-of-the-art imaging methods.
· Thermo Fisher Scientific Inc.
· Emcure Pharmaceuticals Ltd.
· Sigma-Aldrich Co.
· Pfizer Inc.
· Taj Pharmaceuticals Limited
· Novartis International AG
· Teva Pharmaceutical Industries Ltd.
· GE Healthcare
· Siemens Healthineers
· Philips Healthcare
· Shimadzu Corporation
· Toshiba Medical Systems Corporation
· Merck & Co., Inc.
· F. Hoffmann-Le Roche AG
· Arbor Pharmaceuticals, LLC
· Sun Pharmaceutical Industries, Ltd.
· Amneal Pharmaceuticals. LLC
· AstraZeneca
· Carestream Health
· Hitachi Medical Corporation
April 2021: Lineage Cell Therapeutics and Immunomic Therapeutics entered into a licensing agreement for the creation of the allogeneic VAC cancer immunotherapy platform to treat glioblastoma multiforme.
· Primary Tumors
· Secondary Tumors
· Neurological Exam
· Computed Tomography (CT) Scan
· Magnetic Resonance Imaging (MRI)
· Positron Emission Tomography (PET) Scan
· Biopsy
· Molecular Testing
· Electroencephalography (EEG)
· Others
· Surgery
· Chemotherapy
· Radiation Therapy
· Immunotherapy
· Targeted Therapy
· Low Grade Glioma
· High Grade Glioma
· Recurrent High Grade Glioma
· Supratentorial
· Infratentorial
· Hospitals & Clinics
· Diagnostic Centers
· Medical Research Centers
· Others
· North America
- US
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 3.6 Billion |
|
Market Size 2023 |
USD 3.6 Billion |
|
Market Size 2032 |
USD 5.2 Billion |
|
Compound Annual Growth Rate (CAGR) |
5.30% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Type, Diagnosis, Treatment, Grade, Location, End User, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Thermo Fisher Scientific Inc., Emcure Pharmaceuticals Ltd., Sigma-Aldrich Co., Pfizer Inc., Taj Pharmaceuticals Limited, Novartis International AG , Teva Pharmaceutical Industries Ltd., GE Healthcare, Siemens Healthineers, Philips Healthcare, Shimadzu Corporation, Toshiba Medical Systems Corporation, Merck & Co., Inc., F. Hoffmann-Le Roche AG, Arbor Pharmaceuticals, LLC, Sun Pharmaceutical Industries, Ltd., Amneal Pharmaceuticals. LLC, AstraZeneca, Carestream Health, and Hitachi Medical Corporation |
|
Key Market Opportunities |
The growing emphasis on developing better treatment options |
|
Key Market Dynamics |
The growing prevalence of glioblastoma multiforme, increasing R&D, and favorable regulatory scenarios |
The global Glioma Diagnosis and Treatment market size was valued at USD 3.6 Billion in 2022.
The global market is projected to grow at a CAGR of 5.30% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Thermo Fisher Scientific Inc., Emcure Pharmaceuticals Ltd., Sigma-Aldrich Co., Pfizer Inc., Taj Pharmaceuticals Limited, Novartis International AG , Teva Pharmaceutical Industries Ltd., GE Healthcare, Siemens Healthineers, Philips Healthcare, Shimadzu Corporation, Toshiba Medical Systems Corporation, Merck & Co., Inc., F. Hoffmann-Le Roche AG, Arbor Pharmaceuticals, LLC, Sun Pharmaceutical Industries, Ltd., Amneal Pharmaceuticals. LLC, AstraZeneca, Carestream Health, and Hitachi Medical Corporation
The Primary Tumors Type dominated the market in 2022.
The Neurological Exam Diagnosis had the largest share in the global market.
Report Code :
RL65308
Published on :
Sep 2023
Request a Free Sample Report
Speak to Analyst